Urinary biomarkers for podocyte injury: Significance for evaluating the course and prognosis of chronic glomerulonephritis

Full Text

Abstract

Aim. To estimate the degree of podocyte injury in patients with different types of chronic glomerulonephritis (CGN) from the urinary level of podocyte markers and to determine the significance of these indicators as criteria for disease activity and prognosis. Subjects and methods. Seventy-three patients with CGN, including 20 with inactive nephritis (Group 1), 23 with obvious urological syndrome (Group 2), 30 with nephrotic syndrome (NS) (Group 3), among them there were 7 patients with severe NS and 7 with NS concurrent with acute nephritic syndrome, were examined. A control group consisted of 8 healthy individuals. In the examined groups, the degree of podocyturia (PCU) was investigated by flow cytometry using podocalyxin-labeled antibodies and the levels of nephrinuria (NU), heat shock protein 27 (HSP27) in urine, interleukin 6 (IL-6), caspase 9, and vascular endothelial growth factor (VEGF) were estimated by ELISA. Results. The patients with active CGN were found to have a high level of markers for podocyte injury: PCU and NU, which correlate with the magnitude of proteinuria, severity of NS, and degree of podocytopenia. Those with the severest NS, that concurrent with renal dysfunction in particular, were observed to have a progressive imbalance of inflammatory (IL-6), apoptotic (caspase-9), and defensive (HSP27 and VEGF) factors, which displays the incompetence of self-defense mechanisms in podocytes and contributes to the torpid course of CGN. Progressive PCU and NU are a poor prognostic sign indicating the risk of glomerulonephritis. Conclusion. The indicators considered are universal for all patients with CGN running with proteinuria and may be used to monitor the course of the disease; moreover, the damaging factors should be considered in conjunction with the defensive factors.

References

  1. Smoyer W, Mundel P. Regulation of podocyte structur during the development of nephritic syndrome. J Mol Med. 1998;76:172-183.
  2. Huh W, Kim DJ, Kim M-K, Kim YG, Oh HY, Ruotsalainen V, Tryggvason K. Expression of nephrin in acquired human glomerular disease. Nephrol Dial Transplant. 2002;17:478-484.
  3. Kanwar YS, Rosenzweig LJ. Altered glomerular permeability as a result of focal detachment of the visceral epithelium. Kidney Int. 1982;21:565-574.
  4. Kriz W, Greitz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 1998;54:687-697.
  5. Camici M. Urinary detection of podocyte injury. Biomed Pharmacother. 2007;61:245-249.
  6. Yu D, Peterman U, Kunter S, Et Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16(6):1733-1741.
  7. Huber TB, Bensing T. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertension. 2005;14(3):211-216.
  8. Koop K, Eikmans M, Baelde HJ, Kawachi H, de Heer E, Paul LC, Bruijn JA. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol. 2003;14:2063-2071.
  9. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285:40-48.
  10. Mehlen P, Hickey E, Weber LA. Large unphosphorylated aggregates as the active form of hsp27 which controls intracellular reactive oxygen species and glutathione levels and generated a protection against TNFα in NIH-3T3-ras cells. Biochem Biophys Res Commun. 1997;241:187-192.
  11. Preville X, Schultz H, Knauf U, Gaestel M, Arrigo AP. Analysis of the role of Hsp25 phosphorylation reveals the importance of the oligomerization state of this small heat shock protein in its protective function against TNF-α and hydrogen peroxide-induced cell death. J Cell Biochem. 1998;69:436-452.
  12. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, Tang SC. Activation of podocytes by mesangial-derived TNF-a: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008;294:945-955.
  13. Gordon C, Richards N, Howie AJ, Richardson K, Michael J, Adu D, Emery P. Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol. 1991;8:145-149.
  14. Lee SJ, Borsting E, Decleves AE, Singh P, Cunard R. Podocytes express IL-6 and Lipocalin2/Neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury. Nephon Exp Nephrol. 2012;121:86-96.
  15. Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, Tang SC. Activation of podocytes by mesangial-derived TNF-α: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008;294:945-955.
  16. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, Kalluri R, Grande JP. Glomerular expression of nephrin and synaptopodin but not podocin is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant. 2007;22:1136-1143.
  17. Hara A, Wada T, Furuchi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S. Blokade of VEGF accelerates proteinuria via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69(11):1986-1995.
  18. Lemley KV, Lafayette A, Safai G, Derby G, Blouch K, Squarer A, Myers BD. Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475-1485.

Statistics

Views

Abstract: 195

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2015 Chebotareva N.V., Bobkova I.N., Neprintseva N.V., Kozlovskaya L.V., Malkandueva Z.T.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies